| Year |
Citation |
Score |
| 2024 |
Barker RA, Björklund A, Parmar M. The history and status of dopamine cell therapies for Parkinson's disease. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. e2400118. PMID 39058892 DOI: 10.1002/bies.202400118 |
0.332 |
|
| 2023 |
Braun E, Danan-Gotthold M, Borm LE, Lee KW, Vinsland E, Lönnerberg P, Hu L, Li X, He X, Andrusivová Ž, Lundeberg J, Barker RA, Arenas E, Sundström E, Linnarsson S. Comprehensive cell atlas of the first-trimester developing human brain. Science (New York, N.Y.). 382: eadf1226. PMID 37824650 DOI: 10.1126/science.adf1226 |
0.487 |
|
| 2022 |
Bulstrode H, Girdler GC, Gracia T, Aivazidis A, Moutsopoulos I, Young AMH, Hancock J, He X, Ridley K, Xu Z, Stockley JH, Finlay J, Hallou C, Fajardo T, Fountain DM, ... ... Barker RA, et al. Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells. Neuron. PMID 36174572 DOI: 10.1016/j.neuron.2022.09.002 |
0.435 |
|
| 2022 |
Kaiser K, Jang A, Kompanikova P, Lun MP, Prochazka J, Machon O, Dani N, Prochazkova M, Laurent B, Gyllborg D, van Amerongen R, Fame RM, Gupta S, Wu F, Barker RA, et al. Correction: MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. Development (Cambridge, England). 149. PMID 35119069 DOI: 10.1242/dev.200517 |
0.411 |
|
| 2021 |
Qarin S, Howlett SK, Jones JL, Barker RA. The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease. Neuronal Signaling. 5: NS20200083. PMID 34552761 DOI: 10.1042/NS20200083 |
0.306 |
|
| 2021 |
Griffiths WJ, Abdel-Khalik J, Moore SF, Wijeyekoon RS, Crick PJ, Yutuc E, Farrell K, Breen DP, Williams-Gray CH, Theofilopoulos S, Arenas E, Trupp M, Barker RA, Wang Y. The Cerebrospinal Fluid Profile of Cholesterol Metabolites in Parkinson's Disease and Their Association With Disease State and Clinical Features. Frontiers in Aging Neuroscience. 13: 685594. PMID 34526889 DOI: 10.3389/fnagi.2021.685594 |
0.488 |
|
| 2021 |
Barker RA, Björklund A, Frucht SJ, Svendsen CN. Stem Cell-Derived Dopamine Neurons: Will They Replace DBS as the Leading Neurosurgical Treatment for Parkinson's Disease? Journal of Parkinson's Disease. 11: 909-917. PMID 34334425 DOI: 10.3233/JPD-219008 |
0.533 |
|
| 2021 |
Kaiser K, Jang A, Kompanikova P, Lun MP, Prochazka J, Machon O, Dani N, Prochazkova M, Laurent B, Gyllborg D, van Amerongen R, Fame RM, Gupta S, Wu F, Barker RA, et al. MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. Development (Cambridge, England). 148. PMID 34032267 DOI: 10.1242/dev.192054 |
0.451 |
|
| 2021 |
Barbuti PA, Barker RA, Brundin P, Przedborski S, Papa SM, Kalia LV, Mochizuki H. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33963552 DOI: 10.1002/mds.28628 |
0.319 |
|
| 2020 |
Yoon Y, Kim HS, Jeon I, Noh JE, Park HJ, Lee S, Park IH, Stevanato L, Hicks C, Corteling R, Barker RA, Sinden JD, Song J. Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease. Stem Cells (Dayton, Ohio). PMID 32374064 DOI: 10.1002/Stem.3191 |
0.316 |
|
| 2019 |
Barker RA. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nature Medicine. PMID 31263283 DOI: 10.1038/s41591-019-0507-2 |
0.303 |
|
| 2019 |
Kaiser K, Gyllborg D, Procházka J, Salašová A, Kompaníková P, Molina FL, Laguna-Goya R, Radaszkiewicz T, Harnoš J, Procházková M, Potěšil D, Barker RA, Casado ÁG, Zdráhal Z, Sedláček R, et al. WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. Nature Communications. 10: 1498. PMID 30940800 DOI: 10.1038/S41467-019-09298-4 |
0.447 |
|
| 2019 |
Barker R, Mason SL. The hunt for better treatments for Huntington's disease. The Lancet. Neurology. 18: 131-133. PMID 30563777 DOI: 10.1016/S1474-4422(18)30448-4 |
0.315 |
|
| 2019 |
Jensen M, Scott K, Camacho M, Greenland J, Kouli A, Wijeyekoon R, Solim I, Barker R, Williams-Gray C. 123 T and B lymphocyte senescence in parkinson’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 90. DOI: 10.1136/Jnnp-2019-Abn-2.117 |
0.316 |
|
| 2018 |
Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, Tremblay MÈ, Gould P, Rosser AE, Dunnett SB, Piccini P, ... Barker RA, et al. Outcome of cell suspension allografts in a patient with Huntington's disease. Annals of Neurology. PMID 30286516 DOI: 10.1002/Ana.25354 |
0.625 |
|
| 2018 |
Tabrizi SJ, Leavitt B, Landwehrmeyer B, Wild E, Saft C, Barker R, Craufurd D, Rickards H, Rosser A, Priller J, Kordasiewicz H, Czech C, Swayze E, Norris DA, Baumann T, et al. J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington’s disease, results of the first htt-lowering drug trial Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.261 |
0.322 |
|
| 2018 |
Harris K, Mason SL, Barker R. H54 Investigation of the effects of dopamine antagonist medication on cognition in huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.232 |
0.3 |
|
| 2017 |
Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, ... ... Barker RA, et al. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. The Lancet. Neurology. PMID 28629879 DOI: 10.1016/S1474-4422(17)30122-9 |
0.318 |
|
| 2017 |
Stoker TB, Blair NF, Barker RA. Neural grafting for Parkinson's disease: challenges and prospects. Neural Regeneration Research. 12: 389-392. PMID 28469646 DOI: 10.4103/1673-5374.202935 |
0.343 |
|
| 2016 |
Stoker TB, Barker RA. Cell therapies for Parkinson's disease: how far have we come? Regenerative Medicine. PMID 27885887 DOI: 10.2217/rme-2016-0102 |
0.312 |
|
| 2016 |
La Manno G, Gyllborg D, Codeluppi S, Nishimura K, Salto C, Zeisel A, Borm LE, Stott SR, Toledo EM, Villaescusa JC, Lönnerberg P, Ryge J, Barker RA, Arenas E, Linnarsson S. Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. Cell. 167: 566-580.e19. PMID 27716510 DOI: 10.1016/J.Cell.2016.09.027 |
0.527 |
|
| 2016 |
Villaescusa JC, Li B, Toledo EM, Rivetti di Val Cervo P, Yang S, Stott SR, Kaiser K, Islam S, Gyllborg D, Laguna-Goya R, Landreh M, Lönnerberg P, Falk A, Bergman T, Barker RA, et al. A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease. The Embo Journal. PMID 27354364 DOI: 10.15252/Embj.201593725 |
0.537 |
|
| 2016 |
Harris K, Mason S, Barker R. F8 Hippocampal abnormalities in premanifest and early stage huntington’s disease Journal of Neurology, Neurosurgery & Psychiatry. 87: A51.1-A51. DOI: 10.1136/Jnnp-2016-314597.143 |
0.347 |
|
| 2016 |
Palfi S, Gurruchaga JM, Ralph SG, Watts C, Buttery P, Lepetit H, Miskin J, Gouello G, Lavisse S, Fenelon G, Thiriez C, Brugières P, Barker R, Hantraye P, Mitrophanous K. 367. A Dopamine Gene Therapy for Advanced PD: 4 Years Phase I/II Clinical Update Molecular Therapy. 24: S147. DOI: 10.1016/S1525-0016(16)33176-8 |
0.548 |
|
| 2015 |
Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, et al. Tracking Parkinson's: Study Design and Baseline Patient Data. Journal of Parkinson's Disease. PMID 26485428 DOI: 10.3233/Jpd-150662 |
0.333 |
|
| 2014 |
Barker RA. Developing stem cell therapies for Parkinson's disease: waiting until the time is right. Cell Stem Cell. 15: 539-42. PMID 25517462 DOI: 10.1016/j.stem.2014.09.016 |
0.308 |
|
| 2014 |
Zhao JW, Dyson SC, Kriegel C, Tyers P, He X, Fahmy TM, Metcalfe SM, Barker RA. Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease. Disease Models & Mechanisms. 7: 1193-203. PMID 25085990 DOI: 10.1242/Dmm.015859 |
0.311 |
|
| 2014 |
Buttery PC, Barker RA. Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? The Journal of Comparative Neurology. 522: 2802-16. PMID 24610597 DOI: 10.1002/cne.23577 |
0.301 |
|
| 2014 |
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, ... ... Barker RA, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 383: 1138-46. PMID 24412048 DOI: 10.1016/S0140-6736(13)61939-X |
0.48 |
|
| 2014 |
Ali F, Stott SR, Barker RA. Stem cells and the treatment of Parkinson's disease. Experimental Neurology. 260: 3-11. PMID 23298521 DOI: 10.1016/j.expneurol.2012.12.017 |
0.324 |
|
| 2014 |
Ye Z, Rae C, Nombela C, Ham T, Rittman T, Jones S, Rodríguez PV, Coyle-Gilchrist I, Regenthal R, Altena E, Housden C, Maxwell H, Sahakian B, Barker R, Robbins T, et al. Accurate predictive models of Atomextine's and Citalopram's effect on motor inhibition in Parkinson's disease F1000research. 5. DOI: 10.7490/F1000Research.1096208.1 |
0.316 |
|
| 2014 |
Barker R. A02 Natural History In Animal Models of HD; HD Recapitulation? Journal of Neurology, Neurosurgery & Psychiatry. 85: A1-A1. DOI: 10.1136/Jnnp-2014-309032.2 |
0.323 |
|
| 2014 |
Schwab L, Mason S, Begeti F, Barker R. J16 The Effect Of Dopamine Blockade On Cognition In Huntington's Disease Journal of Neurology, Neurosurgery & Psychiatry. 85: A70-A70. DOI: 10.1136/Jnnp-2014-309032.199 |
0.324 |
|
| 2014 |
Mason S, Zhang J, Rowe J, Barker R, Hampshire A. E24 Frontostriatal Abnormalities In Huntington's Disease: An Fmri Study Journal of Neurology, Neurosurgery & Psychiatry. 85: A45-A45. DOI: 10.1136/Jnnp-2014-309032.127 |
0.328 |
|
| 2014 |
Marrinan S, Bajaj N, Barker R, Ben-Shlomo Y, Emmanuel A, Foltynie T, Grosset D, Morris H, Williams N, Wood N, Burn D. 131Gastroparesis Symptoms In Early Parkinson'S Disease Age and Ageing. 43. DOI: 10.1093/Ageing/Afu047.4 |
0.322 |
|
| 2013 |
Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 657-65. PMID 23345280 DOI: 10.1136/Jnnp-2012-302441 |
0.64 |
|
| 2013 |
Delli Carri A, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R, Spaiardi P, Talpo F, Toselli M, Martino G, Barker RA, Dunnett SB, Biella G, et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development (Cambridge, England). 140: 301-12. PMID 23250204 DOI: 10.1242/Dev.084608 |
0.468 |
|
| 2013 |
Barker RA, Barrett J, Mason SL, Björklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. The Lancet. Neurology. 12: 84-91. PMID 23237903 DOI: 10.1016/S1474-4422(12)70295-8 |
0.349 |
|
| 2013 |
Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR. The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 1325-9. PMID 23216520 DOI: 10.1111/Ene.12053 |
0.334 |
|
| 2013 |
Ribeiro D, Laguna Goya R, Ravindran G, Vuono R, Parish CL, Foldi C, Piroth T, Yang S, Parmar M, Nikkhah G, Hjerling-Leffler J, Lindvall O, Barker RA, Arenas E. Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiology of Disease. 49: 118-27. PMID 22940632 DOI: 10.1016/J.Nbd.2012.08.006 |
0.554 |
|
| 2013 |
Grosset D, Malek N, Bajaj N, Barker R, Burn D, Ben–Shlomo Y, Foltynie T, Morris H, Williams N, Wood N. TRACKING PARKINSON'S (THE PROBAND STUDY)–INTERIM REPORT FROM THE FIRST 1000 CASES Journal of Neurology, Neurosurgery & Psychiatry. 84: e2.70-e2. DOI: 10.1136/Jnnp-2013-306573.161 |
0.351 |
|
| 2013 |
Malek N, Bajaj N, Barker R, Ben–Shlomo Y, Burn D, Foltynie T, Morris H, Williams N, Wood N, Grosset D. FAMILY HISTORY IN YOUNG ONSET PARKINSON'S DISEASE Journal of Neurology, Neurosurgery & Psychiatry. 84: e2.69-e2. DOI: 10.1136/Jnnp-2013-306573.160 |
0.304 |
|
| 2012 |
Evans JR, Mason SL, Barker RA. Current status of clinical trials of neural transplantation in Parkinson's disease. Progress in Brain Research. 200: 169-98. PMID 23195419 DOI: 10.1016/B978-0-444-59575-1.00008-9 |
0.312 |
|
| 2012 |
Antoniades CA, Buttery P, FitzGerald JJ, Barker RA, Carpenter RH, Watts C. Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation. Plos One. 7: e32830. PMID 22427894 DOI: 10.1371/Journal.Pone.0032830 |
0.408 |
|
| 2012 |
Lindvall O, Barker RA, Brüstle O, Isacson O, Svendsen CN. Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell. 10: 151-5. PMID 22305565 DOI: 10.1016/j.stem.2012.01.009 |
0.512 |
|
| 2011 |
de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 10: 1049-57. PMID 22071279 DOI: 10.1016/S1474-4422(11)70233-2 |
0.33 |
|
| 2011 |
Barker R. Cell therapies and Parkinson's disease: where next? Interviewed by Emily Culme-Seymour. Regenerative Medicine. 5: 857-61. PMID 21082886 DOI: 10.2217/Rme.10.82 |
0.387 |
|
| 2010 |
Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Progress in Brain Research. 184: 265-94. PMID 20887880 DOI: 10.1016/S0079-6123(10)84014-2 |
0.308 |
|
| 2010 |
Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK, Simpson S, Langbehn D, van Kammen DP. Challenges assessing clinical endpoints in early Huntington disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2595-603. PMID 20623772 DOI: 10.1002/Mds.23337 |
0.313 |
|
| 2009 |
Rowe J, Hughes L, Barker R. Action Selection: the different effects of aging and Parkinson's disease Neuroimage. 47. DOI: 10.1016/S1053-8119(09)71056-0 |
0.329 |
|
| 2008 |
Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochimica Et Biophysica Acta. 1792: 688-702. PMID 19007882 DOI: 10.1016/j.bbadis.2008.10.007 |
0.315 |
|
| 2008 |
Quinn N, Barker R, Wenning G. Are Trials of Intravascular Infusions of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy Currently Justified, and Are They Effective? Clinical Pharmacology & Therapeutics. 83: 663-665. PMID 18425088 DOI: 10.1038/Sj.Clpt.6100454 |
0.347 |
|
| 2008 |
Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurgical Focus. 24: E9. PMID 18341412 DOI: 10.3171/Foc/2008/24/3-4/E8 |
0.522 |
|
| 2007 |
Laguna Goya R, Tyers P, Barker RA. The search for a curative cell therapy in Parkinson's disease. Journal of the Neurological Sciences. 265: 32-42. PMID 17936303 DOI: 10.1016/j.jns.2007.09.006 |
0.335 |
|
| 2006 |
Farrington M, Wreghitt TG, Lever AM, Dunnett SB, Rosser AE, Barker RA. Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature. Cell Transplantation. 15: 279-94. PMID 16898222 DOI: 10.3727/000000006783981927 |
0.455 |
|
| 2005 |
Pyle A, Foltynie T, Tiangyou W, Lambert C, Keers SM, Allcock LM, Davison J, Lewis SJ, Perry RH, Barker R, Burn DJ, Chinnery PF. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Annals of Neurology. 57: 564-7. PMID 15786469 DOI: 10.1002/Ana.20417 |
0.327 |
|
| 2004 |
Harrower TP, Barker RA. Is there a future for neural transplantation? Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 18: 141-53. PMID 15161332 DOI: 10.2165/00063030-200418030-00001 |
0.319 |
|
| 2004 |
Sayles M, Jain M, Barker RA. The cellular repair of the brain in Parkinson's disease--past, present and future. Transplant Immunology. 12: 321-42. PMID 15157925 DOI: 10.1016/J.Trim.2003.12.012 |
0.348 |
|
| 2004 |
Lazic SE, Barker RA. The future of cell-based transplantation therapies for neurodegenerative disorders. Journal of Hematotherapy & Stem Cell Research. 12: 635-42. PMID 14977473 DOI: 10.1089/15258160360732669 |
0.355 |
|
| 2004 |
Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. Xenotransplantation. 11: 60-71. PMID 14962294 DOI: 10.1111/j.1399-3089.2004.00084.x |
0.407 |
|
| 2004 |
Barker R. HUNTINGTON'S DISEASE Brain. 127: 233-234. DOI: 10.1093/Brain/Awh011 |
0.351 |
|
| 2003 |
Hurelbrink CB, Tyers P, Armstrong RJE, Dunnett SB, Barker RA, Rosser AE. Long-Term Hibernation of Human Fetal Striatal Tissue does Not Adversely Affect its Differentiation In Vitro or Graft Survival: Implications for Clinical Trials in Huntington's Disease. Cell Transplantation. 12: 687-695. PMID 28858586 DOI: 10.3727/000000003108747307 |
0.49 |
|
| 2003 |
Hurelbrink CB, Tyers P, Armstrong RJ, Dunnett SB, Barker RA, Rosser AE. Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplantation. 12: 687-95. PMID 14653616 DOI: 10.3727/000000003108747307 |
0.49 |
|
| 2003 |
Rosser AE, Barker RA, Armstrong RJ, Elneil S, Jain M, Hurelbrink CB, Prentice A, Carne C, Thornton S, Hutchinson H, Dunnett SB. Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease. Cell Transplantation. 12: 679-86. PMID 14653615 DOI: 10.3727/000000003108747299 |
0.506 |
|
| 2003 |
Björklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R. Neural transplantation for the treatment of Parkinson's disease. The Lancet. Neurology. 2: 437-45. PMID 12849125 DOI: 10.1016/S1474-4422(03)00442-3 |
0.576 |
|
| 2003 |
Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, Barker RA. Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease. Experimental Brain Research. 151: 204-17. PMID 12783147 DOI: 10.1007/S00221-003-1491-8 |
0.518 |
|
| 2003 |
Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain : a Journal of Neurology. 126: 1127-35. PMID 12690052 DOI: 10.1093/Brain/Awg119 |
0.424 |
|
| 2002 |
Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. Journal of Neurology, Neurosurgery, and Psychiatry. 73: 678-85. PMID 12438470 DOI: 10.1136/Jnnp.73.6.678 |
0.628 |
|
| 2002 |
Armstrong RJ, Hurelbrink CB, Tyers P, Ratcliffe EL, Richards A, Dunnett SB, Rosser AE, Barker RA. The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Experimental Neurology. 175: 98-111. PMID 12009763 DOI: 10.1006/Exnr.2002.7889 |
0.489 |
|
| 2002 |
Hurelbrink CB, Armstrong RJ, Dunnett SB, Rosser AE, Barker RA. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. The European Journal of Neuroscience. 15: 1255-66. PMID 11982636 DOI: 10.1046/J.1460-9568.2002.01959.X |
0.506 |
|
| 2002 |
Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA. Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue. Neuroreport. 13: 481-5. PMID 11930166 |
0.439 |
|
| 2001 |
Armstrong RJ, Rosser AE, Dunnett SB, Barker RA. Neural stem cell technology as a novel treatment for Parkinson's disease. Methods in Molecular Medicine. 62: 289-307. PMID 21318784 DOI: 10.1385/1-59259-142-6:289 |
0.527 |
|
| 2001 |
Armstrong RJ, Harrower TP, Hurelbrink CB, McLaughin M, Ratcliffe EL, Tyers P, Richards A, Dunnett SB, Rosser AE, Barker RA. Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells. Neuroscience. 106: 201-16. PMID 11564430 DOI: 10.1016/S0306-4522(01)00273-1 |
0.482 |
|
| 2001 |
Hurelbrink CB, Armstrong RJ, Luheshi LM, Dunnett SB, Rosser AE, Barker RA. Death of dopaminergic neurons in vitro and in nigral grafts: reevaluating the role of caspase activation. Experimental Neurology. 171: 46-58. PMID 11520120 DOI: 10.1006/Exnr.2001.7749 |
0.424 |
|
| 2001 |
Barker RA. Prospects for the treatment of Parkinson's disease using neural grafts. Expert Opinion On Pharmacotherapy. 1: 889-902. PMID 11249498 DOI: 10.1517/14656566.1.5.889 |
0.311 |
|
| 2001 |
BARKER R. Central Nervous System Diseases: Innovative Animal Models From Lab to Clinic Journal of Neurology, Neurosurgery & Psychiatry. 70: 821d-821. DOI: 10.1136/Jnnp.70.6.821D |
0.336 |
|
| 2001 |
Barker R. CEREBRAL REORGANIZATION OF FUNCTION AFTER BRAIN DAMAGE.: Edited by Harvey S. Levin and Jordan Grafman. 2000. Oxford: Oxford University Press. Price pound39.50. Pp. 392. ISBN 0-19512-026-4. Brain. 124: 1471-1472. DOI: 10.1093/Brain/124.7.1471 |
0.316 |
|
| 2001 |
Harrower T, Cruz G, Copeman L, Richards A, Dunnett S, Barker R. MHC and α Gal Expression in Porcine Fetal Neural Tissue Clinical Science. 100: 13P-13P. DOI: 10.1042/cs100013p |
0.358 |
|
| 2001 |
Cools R, Stefanova E, Barker R, Robbins T, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: The role of prefrontal cortex and basal ganglia revealed by PET Neuroimage. 13: 652. DOI: 10.1016/S1053-8119(01)91995-0 |
0.309 |
|
| 2000 |
Hurelbrink CB, Armstrong RJE, Barker RA, Dunnett SB, Rosser AE. Hibernated Human Fetal Striatal Tissue: Successful Transplantation in a Rat Model of Huntington's Disease. Cell Transplantation. 9: 743-749. PMID 28886291 DOI: 10.1177/096368970000900601 |
0.497 |
|
| 2000 |
Hurelbrink CB, Armstrong RJ, Barker RA, Dunnett SB, Rosser AE. Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease. Cell Transplantation. 9: 743-9. PMID 11202561 DOI: 10.1177/096368970000900601 |
0.497 |
|
| 2000 |
Barker R. Cell Death and Diseases of the Nervous System Journal of Neurology, Neurosurgery, and Psychiatry. 69: 407-407. PMID 10945825 DOI: 10.1136/Jnnp.69.3.407E |
0.321 |
|
| 2000 |
Barker RA, Ratcliffe E, McLaughlin M, Richards A, Dunnett SB. A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 3415-24. PMID 10777804 DOI: 10.1523/Jneurosci.20-09-03415.2000 |
0.457 |
|
| 2000 |
BARKER R. Neural transplantation: an introduction Journal of Neurology, Neurosurgery & Psychiatry. 69: 707b-707. DOI: 10.1136/Jnnp.69.5.707B |
0.386 |
|
| 2000 |
Barker R. Parkinson's disease: the treatment options Journal of Neurology, Neurosurgery, and Psychiatry. 68: 538-538. DOI: 10.1136/Jnnp.68.4.538H |
0.367 |
|
| 1999 |
Barker RA, Ratcliffe E, Richards A, Dunnett SB. Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age. Cell Transplantation. 8: 593-9. PMID 10701488 DOI: 10.1177/096368979900800605 |
0.486 |
|
| 1999 |
Barker RA, Dunnett SB. Functional integration of neural grafts in Parkinson's disease. Nature Neuroscience. 2: 1047-8. PMID 10570477 DOI: 10.1038/15969 |
0.481 |
|
| 1999 |
Barker RA, Dunnett SB, Richards A. The rejection of neural xenotransplants: a role for antibodies. Transplantation. 68: 1091-2. PMID 10551631 DOI: 10.1097/00007890-199910270-00002 |
0.343 |
|
| 1999 |
BARKER R. Diagnosis and Management of Parkinson's Disease Journal of Neurology, Neurosurgery & Psychiatry. 66: 122-123. DOI: 10.1136/Jnnp.66.1.122 |
0.305 |
|
| 1998 |
Dunnett SB, Torres EM, Richards H, Barker RA. Effects of surgical anaesthesia on the viability of nigral grafts in the rat striatum. Cell Transplantation. 7: 567-72. PMID 9853585 DOI: 10.1016/S0963-6897(98)00038-4 |
0.451 |
|
| 1998 |
BARKER R. Clinical Neurology-Parkinsonism. Journal of Neurology, Neurosurgery & Psychiatry. 65: 959f-959f. DOI: 10.1136/Jnnp.65.6.959F |
0.331 |
|
| 1997 |
Annett LE, Torres EM, Clarke DJ, Ishida Y, Barker RA, Ridley RM, Baker HF, Dunnett SB. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. Cell Transplantation. 6: 557-69. PMID 9440865 DOI: 10.1016/S0963-6897(97)00079-1 |
0.722 |
|
| 1996 |
Fricker RA, Barker RA, Fawcett JW, Dunnett SB. A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplantation. 5: 599-611. PMID 8951218 DOI: 10.1016/S0963-6897(96)00087-5 |
0.484 |
|
| 1996 |
Barker R. Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Reviews in the Neurosciences. 7: 187-214. PMID 8916292 DOI: 10.1515/Revneuro.1996.7.3.187 |
0.325 |
|
| 1996 |
Barker RA, Dunnett SB, Faissner A, Fawcett JW. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Experimental Neurology. 141: 79-93. PMID 8797670 DOI: 10.1006/Exnr.1996.0141 |
0.476 |
|
| 1996 |
Barker R. The Comprehensive Management of Parkinson's Disease Journal of Neurology, Neurosurgery & Psychiatry. 60: 248-249. DOI: 10.1136/Jnnp.60.2.248-B |
0.32 |
|
| 1996 |
Barker R. Etiology of Parkinson's Disease Journal of Neurology, Neurosurgery & Psychiatry. 60: 125-125. DOI: 10.1136/Jnnp.60.1.125-B |
0.359 |
|
| 1995 |
Fawcett JW, Barker RA, Dunnett SB. Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Experimental Brain Research. 106: 275-82. PMID 8566192 DOI: 10.1007/Bf00241123 |
0.467 |
|
| 1995 |
Barker RA, Fricker RA, Abrous DN, Fawcett J, Dunnett SB. A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplantation. 4: 173-200. PMID 7539699 |
0.487 |
|
| 1995 |
Barker R. Therapy of Parkinson's Disease. Second Edition Revised and Expanded Journal of Neurology, Neurosurgery & Psychiatry. 59: 663-663. DOI: 10.1136/Jnnp.59.6.663 |
0.341 |
|
| 1995 |
Barker R. Current Concepts in Parkinson's Disease Research Journal of Neurology, Neurosurgery & Psychiatry. 58: 396-396. DOI: 10.1136/Jnnp.58.3.396-C |
0.326 |
|
| 1994 |
Barker R, Dunnett SB. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Experimental Brain Research. 101: 365-74. PMID 7851507 DOI: 10.1007/Bf00227330 |
0.46 |
|
| 1994 |
Barker R, Fricker R, Dunnett SB. 14 - Factors Important in the Survival of Dopamine Neurons in Intracerebral Grafts of Embryonic Substantia Nigra Methods in Neurosciences. 21: 237-252. DOI: 10.1016/B978-0-12-185291-7.50020-5 |
0.574 |
|
| 1994 |
Babensee J, Bäckman C, Baker BJ, Banks W, Barker R, Berry M, Biddle PT, Brem H, Bridges RJ, Broadwell RD, Camarata PJ, Carmichael SW, Carvey PM, Chalmers GR, Boni UD, et al. Contributors to Volume 21 Methods in Neurosciences. 21. DOI: 10.1016/B978-0-12-185291-7.50004-7 |
0.393 |
|
| 1993 |
Barker R, Dunnett S. The biology and behaviour of intracerebral adrenal transplants in animals and man. Reviews in the Neurosciences. 4: 113-146. PMID 7952385 DOI: 10.1515/Revneuro.1993.4.2.113 |
0.54 |
|
| 1993 |
Barker R, Dunnett S, Fawcett J. Immunohistochemical identification of rat adrenal cortical tissue in situ, in vitro, and in intracerebral adrenal grafts. Experimental Neurology. 122: 125-9. PMID 7687964 DOI: 10.1006/Exnr.1993.1113 |
0.484 |
|
| 1993 |
Barker R, Dunnett S, Fawcett J. A selective tachykinin receptor agonist promotes differentiation but not survival of rat chromaffin cells in vitro. Experimental Brain Research. 92: 467-72. PMID 7681011 DOI: 10.1007/Bf00229034 |
0.464 |
|
| 1993 |
Barker RA, Dunnett SB, Fawcett JW. Neurotrophic factors and neural grafts: a growing field Seminars in Neuroscience. 5: 431-441. DOI: 10.1016/S1044-5765(05)80015-6 |
0.463 |
|
| 1989 |
Barker R. Autoimmune Mechanisms in Parkinson's Disease: A Reply International Journal of Neuroscience. 48: 369-372. DOI: 10.3109/00207458909002184 |
0.345 |
|
| Show low-probability matches. |